Restoring regulation – IL-2 therapy in systemic lupus erythematosus

Expert Review of Clinical Immunology

Volumn 12, Issue 11, 2016, Pages 1153-1160

  Humrich, Jens Y ^a   Riemekasten, Gabriela ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

immune homeostasis; immunotherapy; interleukin 2; regulatory T cell; SLE; systemic lupus erythematosus; tolerance

Indexed keywords

INTERLEUKIN 2; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

AUTOIMMUNITY; BIOLOGICAL THERAPY; CELL EXPANSION; DRUG EFFICACY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES;

ANIMALS; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES, REGULATORY;

EID: 84992143164     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2016.1199957     Document Type: Review

References (77)

1. D.A.Morgan, F.W.Ruscetti, R.Gallo Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008.• Identification of IL-2 as a T-cell growth factor.
2. T.Fujita, C.Takaoka, H.Matsui, et al. Structure of the human interleukin 2 gene. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7437–7441.
3. T.Taniguchi, H.Matsui, T.Fujita, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24–30;302(5906):305–310.
4. T.Taniguchi. Structure and function of IL-2 and IL-2 receptors. Behring Inst Mitt. 1992 Apr;91:87–95.
5. T.R.Malek. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–479.
6. T.R.Malek, I.Castro. Interleukin-2 receptor signaling:at the interface between tolerance and immunity. Immunity. 2010 Aug 27;33(2):153–165.
7. B.Sadlack, H.Merz, H.Schorle, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993 Oct 22;75(2):253–261.•• This study provided the first evidence for the role of IL-2 in immune tolerance.
8. B.Sadlack, J.Löhler, H.Schorle, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 1995 Nov;25(11):3053–3059.
9. G.Klebb, I.B.Autenrieth, H.Haber, et al. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol. 1996 Dec;81(3):282–286.
10. J.D.Fontenot, J.P.Rasmussen, M.A.Gavin, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6(11):1142–1151.• One of the first studies that proved that IL-2 is a key factor in Treg biology.
11. L.M.D’Cruz, L.Klein. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005 Nov;6(11):1152–1159.
12. R.Setoguchi, S.Hori, T.Takahashi, et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005 Mar 7;201(5):723–735.• One of the first studies that proved that IL-2 is a key factor in Treg biology.
13. A.L.Bayer, A.Yu, T.R.Malek. Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunology. 2007 Apr 1;178(7):4062–4071.
14. S.Brandenburg, T.Takahashi, M.de la Rosa, et al. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol. 2008 Jun;38(6):1643–1653.
15. S.Sakaguchi. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr;6(4):345–352.
16. S.A.Rosenberg, J.C.Yang, S.L.Topalian, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994 Mar 23–30;271(12):907–913.
17. M.Ahmadzadeh, S.A.Rosenberg. IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood. 2006 Mar 15;107(6):2409–2414.
18. S.Sakaguchi, N.Sakaguchi, M.Asano, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunology. 1995 Aug 1;155(3):1151–1164.•• The ‘birth’ of regulatory T cells and of the modern concepts of immune regulation and tolerance. A real milestone.
19. J.D.Fontenot, M.A.Gavin, A.Y.Rudensky. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003 Apr;4(4):330–336.
20. S.Sakaguchi, M.Miyara, C.M.Costantino, et al. FOXP3+ regulatory T cells in the human immune system. Nat Revi Immunol. 2010 Jul;10(7):490–500.
21. J.M.Kim, J.P.Rasmussen, A.Y.Rudensky. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007 Feb;8(2):191–197.
22. J.M.Kim, A.Rudensky. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev. 2006 Aug;212:86–98.
23. S.Sakaguchi, T.Yamaguchi, T.Nomura, et al. T cells and immune tolerance. Cell. 2008 May 30;133(5):775–787.
24. K.Wing, S.Sakaguchi. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010 Jan;11(1):7–13.
25. M.Miyara, G.Gorochov, M.Ehrenstein, et al. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 2011 Oct;10(12):744–755.
26. J.Y.Humrich, T.Kamradt, G.Riemekasten. Regulatory T cells and rheumatic diseases. Z Rheumatol. 2015 Feb;74(1):26–32.
27. L.S.Taams, D.B.Palmer, A.N.Akbar, et al. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology. 2006 May;118(1):1–9.
28. E.L.Masteller, Q.Tang, J.A.Bluestone. Antigen-specific regulatory T cells – ex vivo expansion and therapeutic potential. Semin Immunol. 2006 Apr;18(2):103–110.
29. J.L.Riley, C.H.June, B.R.Blazar. Human T regulatory cell therapy:take a billion or so and call me in the morning. Immunity. 2009 May;30(5):656–665.
30. J.A.Bluestone, Q.Tang. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005 Dec;17(6):638–642.
31. M.Miyara, Y.Ito, S.Sakaguchi. TRE G-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol. 2014 Sep;10(9):543–551.
32. M.Miyara, Z.Amoura, C.Parizot, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunology. 2005 Dec 15;175(12):8392–8400.
33. J.L.Suen, H.T.Li, Y.J.Jong, et al. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology. 2009 Jun;127(2):196–205.
34. K.J.Scalapino, Q.Tang, J.A.Bluestone, et al. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunology. 2006 Aug 1;177(3):1451–1459.
35. J.Y.Humrich, H.Morbach, R.Undeutsch, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):204–209.•• First proof of the pathogenetic relevance of IL-2 deficiency and related Treg defects in murine lupus.
36. M.Bonelli, K.von Dalwigk, A.Savitskaya, et al. Foxp 3 expression in CD4+ T cells of patients with systemic lupus erythematosus:a comparative phenotypic analysis. Ann Rheum Dis. 2008 May;67(5):664–671.
37. M.Bonelli, A.Savitskaya, C.W.Steiner, et al. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunology. 2009 Feb 1;182(3):1689–1695.
38. C.von Spee-Mayer, E.Siegert, D.Abdirama, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2015 Aug;31.• First proof-of-concept study of low-dose IL-2 therapy in SLE patients.
39. O.Weigert, C.von Spee, R.Undeutsch, et al. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther. 2013;15(1):R35.
40. J.B.Engler, R.Undeutsch, L.Kloke, et al. Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Ann Rheum Dis. 2011 Dec;70(12):2176–2183.
41. B.H.Nelson. IL-2, regulatory T cells, and tolerance. J Immunology. 2004 Apr 1;172(7):3983–3988.
42. H.Suzuki, T.M.Kundig, C.Furlonger, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995 Jun 9;268(5216):1472–1476.
43. Y.Feng, A.Arvey, T.Chinen, et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell. 2014 Aug 14;158(4):749–763.
44. A.Ballesteros-Tato, B.León, B.A.Graf, et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity. 2012 May 25;36(5):847–856.
45. A.Laurence, C.M.Tato, T.S.Davidson, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007 Mar;26(3):371–381.
46. Q.Tang, J.Y.Adams, C.Penaranda, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008 May;28(5):687–697.
47. K.E.Webster, S.Walters, R.E.Kohler, et al. In vivo expansion of Treg cells with IL-2-mAb complexes:induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009 Apr 13;206(4):751–760.
48. Y.Grinberg-Bleyer, A.Baeyens, S.You, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010 Aug 30;207(9):1871–1878.
49. M.J.Dauphinee, S.B.Kipper, D.Wofsy, et al. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunology. 1981 Dec;127(6):2483–2487.
50. D.Wofsy, E.D.Murphy, J.B.Roths, et al. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med. 1981 Nov 1;154(5):1671–1680.
51. M.Linker-Israeli, A.C.Bakke, R.C.Kitridou, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunology. 1983 Jun;130(6):2651–2655.• First study providing evidence for IL-2 deficiency in SLE patients.
52. J.C.Gutierrez-Ramos, J.L.Andreu, Y.Revilla, et al. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature. 1990 Jul 19;346(6281):271–274.
53. E.E.Solomou, Y.T.Juang, M.F.Gourley, et al. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunology. 2001 Mar 15;166(6):4216–4222.
54. K.Tenbrock, Y.T.Juang, M.F.Gourley, et al. Antisense cyclic adenosine 5ʹ-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J Immunology. 2002 Oct 15;169(8):4147–4152.
55. Y.T.Juang, Y.Wang, E.E.Solomou, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest. 2005 Apr;115(4):996–1005.
56. C.G.Katsiari, G.C.Tsokos. Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmun Rev. 2006 Feb;5(2):118–121.
57. Y.T.Juang, T.Rauen, Y.Wang, et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J Biol Chem. 2011 Jan 21;286(3):1795–1801.
58. C.M.Hedrich, T.Rauen, G.C.Tsokos. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene:implications in systemic lupus erythematosus. J Biol Chem. 2011 Dec 16;286(50):43429–43436.
59. C.M.Hedrich, J.C.Crispin, T.Rauen, et al. cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16606–16611.
60. T.Rauen, C.M.Hedrich, K.Tenbrock, et al. cAMP responsive element modulator:a critical regulator of cytokine production. Trends Mol Med. 2013 Apr;19(4):262–269.
61. D.Gómez-Martín, M.Díaz-Zamudio, J.C.Crispín, et al. Interleukin 2 and systemic lupus erythematosus:beyond the transcriptional regulatory net abnormalities. Autoimmun Rev. 2009 Sep;9(1):34–39.
62. M.Mizui, T.Koga, L.A.Lieberman, et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunology. 2014 Sep 1;193(5):2168–2177.
63. K.Ohl, A.Wiener, A.Schippers, et al. Interleukin-2 treatment reverses effects of cAMP-responsive element modulator alpha-over-expressing T cells in autoimmune-prone mice. Clin Exp Immunol. 2015 Jul;181(1):76–86.
64. D.Saadoun, M.Rosenzwajg, F.Joly, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067–2077.•• Pioneer study for the clinical implementation of low-dose IL-2 therapy in immune-mediated diseases.
65. J.Koreth, K.Matsuoka, H.T.Kim, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 1;365(22):2055–2066.•• Pioneer study for the clinical implementation of low-dose IL-2 therapy in immune-mediated diseases.
66. O.Boyer, D.Saadoun, J.Abriol, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood. 2004 May 1;103(9):3428–3430.
67. E.Zorn, H.T.Kim, S.J.Lee, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15;106(8):2903–2911.
68. J.C.Crispin, J.Alcocer-Varela. Interleukin-2 and systemic lupus erythematosus – fifteen years later. Lupus. 1998;7(4):214–222.
69. S.A.Long, M.Rieck, S.Sanda, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes. 2012 Sep;61(9):2340–2348.
70. S.A.Long, J.H.Buckner, C.J.Greenbaum. IL-2 therapy in type 1 diabetes:‘trials’ and tribulations. Clin Immunol. 2013 Dec;149(3):324–331.
71. M.Rosenzwajg, G.Churlaud, R.Mallone, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48–58.
72. M.Rosenzwajg, G.Churlaud, A.Hartemann, et al. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes. Curr Diab Rep. 2014 Dec;14(12):553.
73. E.Castela, F.Le Duff, C.Butori, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014 Jul;150(7):748–751.
74. J.Y.Humrich, C.von Spee-Mayer, E.Siegert, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015 Apr;74(4):791–792.• Case report on the first SLE patient treated with low doses of IL-2.
75. M.A.Cooper, T.A.Fehniger, S.C.Turner, et al. Human natural killer cells:a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001 May 15;97(10):3146–3151.
76. K.Matsuoka, J.Koreth, H.T.Kim, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 3;5(179):179ra43.
77. D.Klatzmann, A.K.Abbas. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Revi Immunol. 2015 May;15(5):283–294.